Cardiovascular risk markers in women with metabolic syndrome at the menopausal transition using multimodal non-drug therapies

Aim. To study the effect of non-drug strategies on the main markers of cardiovascular risk in women with menopausal disorders and metabolic syndrome (MS).

Material and methods. Three hundred women aged 45-50 years with disorders during the menopausal transition and MS were ranked in 5 groups. In group I, following methods were used: standard treatment, physiotherapy, balneotherapy, multivitamins and minerals, as well as physical factors (vibration therapy, chromotherapy, melotherapy, aromatherapy, aeroionotherapy). In group II, chromotherapy was excluded from the above methods, in group III — vibration therapy, in group IV, physiotherapy was not used, in group V only standard treatment was used. We assessed blood pressure (BP), lipid profile, levels of glucose and serum insulin, and estimated the HOMA-IR index (Homeostasis Model Assessment — Insulin Resistance).

Results. Complex treatment using physical factors contributed to the optimization of BP control, improved carbohydrate and fat metabolism. The simultaneous use of all the above physical factors made it possible to improve BP control and most significantly reduce after 6 months of therapy in patients with mild climacteric syndrome the HOMAIR index by 56,2% and the atherogenic index by 31,2%, and in patients with moderate climacteric syndrome — by 57,2% and 30,5%, respectively (p< 0,0001). The decrease in the Green test was 55,3% and 39,9%, respectively (p<0,0001).

Conclusion. Non-drug strategies with physiotherapy help to reduce the manifestation of cardiovascular risk in women with MS at the menopausal transition, positively affecting modifiable factors and normalizing the activity of hypothalamicpituitary-gonadal axis. The priority is the simultaneous use of vibration therapy, chromotherapy, melotherapy, aromatherapy and aeroionotherapy.

1. Huang Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematicreview and meta-analysis. BMJ. 2016;355(i5953):1-11. doi:10.1136/bmj.i5953.

2. Eshtiaghi R, Esteghamati A, Nakhjavani M. Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas. 2010;65(3):262-6. doi:10.1016/j.maturitas.2009.11.004.

3. Mumusoglu S, Yildiz BO. Metabolic Syndrome During Menopause. Curr Vasc Pharmacol. 2019;17(6):595-603. doi:10.2174/1570161116666180904094149.

4. Cengiz H, Kaya C, Suzen Caypinar S, Alay I. The relationship between menopausal symptoms and metabolic syndrome in postmenopausal women. J Obstet Gynaecol. 2019;39(4):529-33. doi:10.1080/01443615.2018.1534812.

5. Tuomikoski P, Savolainen-Peltonen H. Vasomotor symptoms and metabolic syndrome. Maturitas. 2017;97:61‐5. doi:10.1016/j.maturitas.2016.12.010.

6. Willi J, Ehlert U. Assessment of perimenopausal depression: A review. J Affect Disord. 2019;249:216-22. doi:10.1016/j.jad.2019.02.029.

7. Stute P, Spyropoulou A, Karageorgiou V, et al. Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement. Maturitas. 2020;131:91-101. doi:10.1016/j.maturitas.2019.11.002.

8. Zhang Y, Chen Y, Ma L. Depression and cardiovascular disease in elderly: Current understanding. J Clin Neurosci. 2018;47:1-5. doi:10.1016/j.jocn.2017.09.022.

9. Zimmet P, Alberti KGMM, Stern N, et al. The Circadian Syndrome: is the Metabolic Syndrome and much more! J Intern Med. 2019;286(2):181-91. doi:10.1111/joim.12924.

10. Lemche AV, Chaban OS, Lemche E. Depression contributing to dyslipidemic cardiovascular risk in the metabolic syndrome. J Endocrinol Invest. 2017;40(5):539-46. doi:10.1007/s40618-016-0601-y.

11. Stevenson JC, Tsiligiannis S, Panay N. Curr Vasc Pharmacol. 2019;17(6):591-4. doi:10.2174/1570161116666181002145340.

12. Chedraui P, Pérez-López FR. Metabolic syndrome during female midlife: what are the risks? Climacteric. 2019;22(2):127-32. doi:10.1080/13697137.2018.1561666.

13. Marlatt KL, Redman LM, Beyl RA, et al. Racial differences in body composition and cardiometabolic risk during the menopause transition: a prospective, observational cohort study. Am J Obstet Gynecol. 2020;222(4):365.e1-365.e18. doi:10.1016/j.ajog.2019.09.051.

14. Smirnova EN, Turuntseva ON, Shulkina SG. Endothelial dysfunction in obese women in the early postmenopausal period. Vyatsky Medical Bulletin. 2017;1(53):23-7. (In Russ.)

15. Anti-age strategies and menopausal hormone therapy: from the regulation of cell metabolism to maintaining the quality of life. Gynecology. 2018;20(3):42-7. (In Russ.) doi:10.26442/2079-5696_2018.3.42-47.

16. Ward E, Gold EB, Johnson WO, et al. Patterns of Cardiometabolic Health as Midlife Women Transition to Menopause: A Prospective Multiethnic Study. J Clin Endocrinol Metab. 2019;104(5):1404‐12. doi:10.1210/jc.2018-00941.

17. Cobin RH, Goodman NF. AACE Reproductive Endocrinology Scientific Committee. American associanione of clinical endocrinologists and American college of endocrinology positione statement on menopause — 2017. Endocr Pract. 2017;23(7):869‐80. doi:10.4158/EP171828.PS.

18. Anagnostis P, Paschou SA, Katsiki N, et al. Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now? Curr Vasc Pharmacol. 2019;17(6):564-72. doi:10.2174/1570161116666180709095348.

19. Oliver-Williams C, Glisic M, Shahzad S, et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum Reprod Update. 2019;25(2):257‐71. doi:10.1093/humupd/dmy039.

20. Kostromina AA, Radzinsky VE, Khamoshina MB, et al. Risk Factors for Severe Menopausal Syndrome: a Clinicostatistical Study. Doctor.Ru. 2017;9(138):12-6. (In Russ.)

21. Wassertheil-Smoller S, Kaplan RC, Salazar CR. Stroke findings in the Women’s Health Initia-tive. Semin. Reprod. Med. 2014;32(6):438-46. doi:10.1055/s-0034-1384627.

22. Yureneva SV, Ermakova EI. Management of women with menopausal disorders (review of clinical guidelines). Reproduction problems. 2017;23(5):115-22. (In Russ.) doi:10.17116/repro2017235115-122.

23. Recommendations of experts of the All-Russian Scientific Society of Cardiology on the diagnosis and treatment of metabolic syndrome (second revision). Practical medicine. 2010;5(44):81-101. (In Russ.)

24. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by Representatives of 10 Societies and by Invited experts) Developed With the Special Contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381. doi:10.1093/eurheartj/ehw106.

25. Frolkov VK, Nagornev SN, Bobrovnitsky IP. The use of mineral water for drinking use to increase functional reserves and nonspecific resistance of the body. Russian Journal of Rehabilitation Medicine. 2017;3:34-61. (In Russ.)

26. Jamilian M, Sabzevar NK, Asemi Z. The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, PlaceboControlled Trial. Horm Metab Res. 2019;51(2):100-5. doi:10.1055/a-0749-6431.

27. Ko SH, Kim HS. Menopause-Associated Lipid Metabolic Disorders and Foods Beneficial for Postmenopausal Women. Nutrients. 2020;12(1):202. doi:10.3390/nu12010202.

28. Bliznichenko MV. Music and music therapy in the evolution of mankind. Kant. 2014;3(12):146-8. (In Russ.)

29. Roozbeh N, Ghazanfarpour M, Khadivzadeh T, et al. Effect of Lavender on Sleep, Sexual Desire, Vasomotor, Psychological and Physical Symptom among Menopausal and Elderly Women: A Systematic Review. J Menopausal Med. 2019;25(2):88-93. doi:10.6118/jmm.18158.

30. Schneider R, Singer N, Singer T. Medical aromatherapy revisited-Basic mechanisms, critique, and a new development. Hum Psychopharmacol. 2019;34(1):e2683. doi:10.1002/hup.2683.

31. Boryak VP. Correction of disturbed vagosympathetic balance with the help of phytoaeroionization. Spa medicine. 2013;2:30-3. (In Russ.)

32. Physiotherapy and balneology. Book I. Ed. Bogolyubova V.M. M.: BINOM Publishing House, 2018. p. 408. (In Russ.) ISBN 978-5-9518-0273-6